MDS Revised - International Prognostic Scoring System (IPSS-R)

Assess mortality and progression to acute myeloid leukemia in myelodysplastic syndrome

Questions

1.Age
2.BM Blasts?
3.Karyotype?
4.Hemoglobin?
5.ANC?
6.Platelets?

About

Myelodysplastic syndromes are a heterogeneous group of diseases with variable outcomes. To refine the original IPSS, international MDS databases were combined for analysis (yielding a total population of n=7012). Modeling of prognostic risk was based on multivariate analysis of survival time and time to AML transformation.

Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the revised IPSS, but with refinement of the category thresholds and addition of age, performance status, serum ferritin, and LDH.

References

Greenberg et al.

Revised International Prognostic Scoring System for Myelodysplastic Syndromes.

Blood 2012 September 20, 120 (12): 2454-65

Created by on 04/07/2017

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Age

Years
0/6 completed